Neurobo Pharmaceuticals Stock Annual Yield
NRBODelisted Stock | USD 2.26 0.06 2.59% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
Neurobo |
Neurobo Pharmaceuticals Company Annual Yield Analysis
Neurobo Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Neurobo Pharmaceuticals has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
All Next | Launch Module |
Neurobo Fundamentals
Return On Equity | -1.61 | |||
Return On Asset | -0.74 | |||
Current Valuation | (1.18 M) | |||
Shares Outstanding | 8.62 M | |||
Shares Owned By Insiders | 65.23 % | |||
Shares Owned By Institutions | 12.71 % | |||
Number Of Shares Shorted | 34.27 K | |||
Price To Earning | (1.44) X | |||
Price To Book | 1.57 X | |||
Revenue | 7 K | |||
EBITDA | (15.88 M) | |||
Net Income | (12.47 M) | |||
Cash And Equivalents | 8.85 M | |||
Cash Per Share | 9.96 X | |||
Total Debt | 203 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 8.07 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (10.8 M) | |||
Short Ratio | 0.87 X | |||
Earnings Per Share | (4.29) X | |||
Target Price | 26.67 | |||
Beta | -0.28 | |||
Market Capitalization | 20.33 M | |||
Total Asset | 22.78 M | |||
Retained Earnings | (108.27 M) | |||
Working Capital | 16.55 M | |||
Current Asset | 21.62 M | |||
Current Liabilities | 11.75 M | |||
Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
0.81 | PPERY | Bank Mandiri Persero | PairCorr |
0.8 | PPERF | Bank Mandiri Persero | PairCorr |
0.75 | BKRKF | PT Bank Rakyat | PairCorr |
0.81 | BKRKY | Bank Rakyat | PairCorr |
Moving against Neurobo Stock
0.82 | CSCO | Cisco Systems | PairCorr |
0.78 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
0.78 | HD | Home Depot | PairCorr |
0.74 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
0.71 | DIS | Walt Disney | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |